The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CSL Behring; Eisai; Incyte; Karyopharm Therapeutics; Roche; Seagen; SOBI
Research Funding - Amgen; Biotest; Bristol-Myers Squibb; Celgene; CSL Behring; Eisai; Hexal; Medac; Octapharm; Takeda
Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA.
 
Diana Lüftner
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; L'Oreal; Lilly; Novartis; Pfizer; Sandoz; Tesaro
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; L'Oreal; Lilly; Novartis; Pfizer; Sandoz; Tesaro
Speakers' Bureau - Amgen; AstraZeneca; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; L'Oreal; Lilly; Novartis; Pfizer; Sandoz; Tesaro
Research Funding - Novartis
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; L'Oreal; Lilly; Novartis; Pfizer; Sandoz; Tesaro
 
Cosima Brucker
No Relationships to Disclose
 
Thomas Decker
Consulting or Advisory Role - Novartis
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche
 
Thomas Göhler
No Relationships to Disclose
 
Christian Jackisch
Honoraria - AstraZeneca; Exact Sciences; Lilly; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Genomic Health; Genomic Health; Novartis; Roche; Tesaro
Research Funding - Genomic Health (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis; Roche
 
Jan Janssen
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ipsen; Johnson & Johnson; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Johnson & Johnson; Novartis; Pfizer; Roche
 
Andreas Koehler
Stock and Other Ownership Interests - Roche
Honoraria - Novartis; Stada
Consulting or Advisory Role - Agendia; Amgen; MSD; Novartis; Onkovis; Pfizer; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Celgene; Onkovis
 
Kerstin Luedtke-Heckenkamp
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai Germany; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Merck Serono; Novartis; Roche Pharma AG; Seagen
Research Funding - Eisai Germany (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Celgene/Bristol-Myers Squibb; Novartis; Pfizer; Roche Pharma AG
 
Marion Van Mackelenbergh
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo; Genomic Health; Gilead Sciences; GlaxoSmithKline; Lilly; Molecular Health; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Genomic Health; Gilead Sciences; GlaxoSmithKline; Lilly; Molecular Health; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Travel, Accommodations, Expenses - Daiichi Sankyo; Lilly; Novartis
 
Frederik Marmé
Honoraria - AGENDIA; Amgen; AstraZeneca; Celgene; Clovis Oncology; Clovis Oncology; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics (Inst); Lilly; MSD Oncology; Myriad Genetics; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche/Genentech; Seagen; Tesaro
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); CureVac; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics (Inst); Pfizer; Roche (Inst); Tesaro; Vaccibody (Inst)
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Tesaro (Inst); Vaccibody (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Arnd Nusch
No Relationships to Disclose
 
Beate Rautenberg
Honoraria - Amgen; Clovis Oncology; Lilly; MSD; Roche; WPO
Consulting or Advisory Role - Lilly; MSD; Roche
Research Funding - Lilly; Roche
Travel, Accommodations, Expenses - Daiichi Sankyo; Lilly; Roche
 
Toralf Reimer
Consulting or Advisory Role - Pfizer
Research Funding - Else Kröner-Fresenius-Stiftung; German Cancer Aid
Other Relationship - Pfizer
 
Marcus Schmidt
Honoraria - AstraZeneca; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; BioNTech; Eisai; Lilly; MSD Oncology; Novartis; Pantarhei Bioscience; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - AstraZeneca (Inst); BioNTech (Inst); Genentech/Roche (Inst); Novartis (Inst); Pantarhei Bioscience (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - EP 2390370 B1 A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent; EP 2951317 B1 METHOD FOR PREDICTING THE BENEFIT FROM INCLUSION OF TAXANE IN A CHEMOTHERAPY REGIMEN IN PATIENTS WITH BREAST CANCER
 
Rudolf Weide
No Relationships to Disclose
 
Pauline Wimberger
Honoraria - Amgen; AstraZeneca; Eisai; MSD Oncology; Novartis/Pfizer; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Amgen; AstraZeneca; MSD Oncology; Novartis; PharmaMar; Roche Pharma AG; Tesaro
Travel, Accommodations, Expenses - Roche Pharma AG
 
Naiba Nabieva
Employment - Novartis
 
Christian Roos
Employment - Novartis
 
Achim Woeckel
Consulting or Advisory Role - Amgen; AstraZeneca; Aurikamed; Celgene; Clovis Oncology; Eisai; Genomic Health; Lilly; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sirtex Medical; Tesaro